Company
(location)

Product

Description

Indication

Status

Date

Cancer

Celgene Corp. (Summit, N.J.)

Otezla

Apremilast

Behçet's disease with oral ulcers

Phase III RELIEF data showed that, at week 12, the area under the curve (AUC) for the number of oral ulcers was statistically significantly reduced with 30 mg twice daily vs. placebo (129.5 vs. 222.1; p<0.0001), the trial's primary endpoint; statistically significant improvements were also seen with in multiple secondary endpoints, including oral ulcer pain (p<0.0001), overall disease activity (Behçet's Syndrome Activity Score: p<0.0001; Behçet's Disease Current Activity Index: p=0.0335) and quality of life (p=0.0003)

2/20/18

Glenmark Pharmaceuticals Inc. (Paramus, N.J.)

GBR 830

Anti-OX40 monoclonal antibody

Moderate-to-severe atopic dermatitis (AD)

Phase IIa data on 40 patients who had skin biopsies showed that it had an effect on AD-related disease biomarkers; clinical improvement in Eczema Area and Severity Index scores was observed in 17 out of 23 patients treated with it; it was safe and well-tolerated

2/20/18

Janssen Pharmaceutical Co. (subsidiary of New Brunswick, N.J.-based Johnson & Johnson)

Tremfya

Guselkumab

Moderate to severe plaque psoriasis

Phase III VOYAGE 2 data that showed a vast majority of patients achieved at least 90% improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28 and maintained a PASI 90 response with continuous treatment through week 72; data also demonstrated that a vast majority of patients originally randomized to Tremfya, but withdrawn from treatment at week 28, regained a PASI 90 response within six months of initiating Tremfya retreatment

2/20/18

Ortho Dermatologics (division of Valeant Pharmaceuticals North America LLC, of Laval, Quebec)

Siliq

Brodalumab

Psoriasis

Analysis of the phase III clinical trial AMAGINE-1, which evaluated mental health comorbidities associated with psoriasis, such as anxiety and depression, suggested that treatment reduced anxiety and depression in patients with moderate-to-severe plaque psoriasis; after 12 weeks of SILIQ treatment, patients experienced a decrease in depression and anxiety HADS (hospital anxiety and depression scale) scores (mean scores decreased by 2.1 and 1.8, respectively) while scores remained unaffected in those receiving placebo

2/20/18


Notes

The date indicated refers to the BioWorld Today issue in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.

 

No Comments